Source:http://linkedlifedata.com/resource/pubmed/id/19244548
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2009-4-24
|
| pubmed:abstractText |
We examined the therapeutic activity of betamethasone disodium 21-phosphate (BP) encapsulated in biocompatible and biodegradable blended nanoparticles of poly (D,L-lactic/glycolic acid) (PLGA)/poly(D,L-lactic acid) (PLA) homopolymers and polyethylene glycol (PEG)-block-PLGA/PLA copolymers (stealth nanosteroid) in experimental arthritis models. Various stealth nanosteroids with a size of 45 to 115 nm were prepared and then intravenously administered to rats with adjuvant arthritis (AA) rats and mice with anti-type II collagen antibody-induced arthritis (AbIA). The accumulation of stealth nanoparticles with Cy7 in inflamed joints was determined using an in vivo imaging system. The type A stealth nanosteroid, composed of PLA (2.6 kDa) and PEG (5 kDa)-PLA (3 kDa), with a PEG content of 10% and a diameter of 115 nm, exhibited the highest anti-inflammatory activity. In AA rats, a 35% decrease in paw inflammation was obtained in 1 day and maintained for 9 days with a single injection of the type A stealth nanosteroid (40 microg of BP), whereas the same does of nonstealth nanosteroid and 3 times higher free BP showed a significantly weaker response. In AbIA mice, a single injection of the type A stealth nanosteroid (3 microg of BP) resulted in complete remission of the inflammatory response after 1 week. Furthermore, in AbAI mice, the accumulation of type A stealth nanoparticles in inflamed joints was shown to parallel the severity of inflammation. The observed strong therapeutic benefit obtained with the type A stealth nanosteroid in experimental arthritis may have been due to prolonged blood circulation and targeting to the inflamed joint in addition to its sustained release in situ.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Betamethasone,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Carriers,
http://linkedlifedata.com/resource/pubmed/chemical/Glucocorticoids,
http://linkedlifedata.com/resource/pubmed/chemical/Lactic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Polyethylene Glycols,
http://linkedlifedata.com/resource/pubmed/chemical/Polyglycolic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/betamethasone sodium phosphate,
http://linkedlifedata.com/resource/pubmed/chemical/polylactic acid-polyglycolic acid...
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
1521-0103
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
329
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
412-7
|
| pubmed:meshHeading |
pubmed-meshheading:19244548-Animals,
pubmed-meshheading:19244548-Arthritis, Experimental,
pubmed-meshheading:19244548-Betamethasone,
pubmed-meshheading:19244548-Drug Carriers,
pubmed-meshheading:19244548-Drug Compounding,
pubmed-meshheading:19244548-Female,
pubmed-meshheading:19244548-Glucocorticoids,
pubmed-meshheading:19244548-Injections, Intravenous,
pubmed-meshheading:19244548-Lactic Acid,
pubmed-meshheading:19244548-Male,
pubmed-meshheading:19244548-Mice,
pubmed-meshheading:19244548-Mice, Inbred BALB C,
pubmed-meshheading:19244548-Nanoparticles,
pubmed-meshheading:19244548-Polyethylene Glycols,
pubmed-meshheading:19244548-Polyglycolic Acid,
pubmed-meshheading:19244548-Rats,
pubmed-meshheading:19244548-Rats, Inbred Lew,
pubmed-meshheading:19244548-Tissue Distribution,
pubmed-meshheading:19244548-Treatment Outcome
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Treatment of experimental arthritis with stealth-type polymeric nanoparticles encapsulating betamethasone phosphate.
|
| pubmed:affiliation |
Institute of Drug Delivery System, Research Center for Medical Sciences, The Jikei University School of Medicine, Tokyo, Japan.
|
| pubmed:publicationType |
Journal Article
|